论文部分内容阅读
目的:观察鲑鱼降钙素结合碳酸钙对老年性骨质疏松骨代谢指标的影响。方法:选取2014年1月-2015年6月我院收治的80例老年性骨质疏松患者,将患者随机分为对照组和治疗组,每组40例,对照组给予碳酸钙治疗,观察组给予鲑鱼降钙素结合碳酸钙进行治疗,治疗周期均为24周,比较两组患者的骨代谢指标的变化情况。结果:治疗结束后,治疗组的骨密度、血清骨钙素较治疗前相比,出现明显升高(P<0.05),对照组治疗后的骨密度、血清骨钙素较治疗前相比无明显变化(P>0.05),两组比较可见,治疗组明显高于对照组(P<0.05);治疗后,治疗组的尿钙/肌酐值、血骨碱性磷酸酶与治疗前相比出现明显下降(P<0.05),对照组治疗后无明显变化(P>0.05),两组比较治疗组明显较低(P<0.05);治疗后,两组的血磷、血钙均无明显变化(P>0.05)。结论:对老年性骨质疏松患者采用鲑鱼降钙素结合碳酸钙进行治疗,能够明显改善患者的骨代谢异常,对骨生成具有促进作用,值得临床推广。
Objective: To observe the effect of salmon calcitonin combined with calcium carbonate on bone metabolism in senile osteoporosis. Methods: From January 2014 to June 2015, 80 patients with senile osteoporosis admitted to our hospital were selected. The patients were randomly divided into control group and treatment group, 40 cases in each group. The control group was treated with calcium carbonate. The observation group Salmon calcitonin combined with calcium carbonate for treatment, treatment cycles were 24 weeks, comparing the two groups of patients with changes in bone metabolism. Results: At the end of treatment, the bone mineral density and serum osteocalcin in the treatment group were significantly higher than those before treatment (P <0.05). The bone mineral density and serum osteocalcin in the control group were significantly lower than those before treatment (P> 0.05), the two groups were seen, the treatment group was significantly higher than the control group (P <0.05); after treatment, the treatment group, urinary calcium / creatinine, blood alkaline phosphatase compared with before treatment (P <0.05). There was no significant change in the control group after treatment (P> 0.05), and the two groups were significantly lower than the treatment group (P <0.05); after treatment, there was no significant change in serum phosphorus and serum calcium (P> 0.05). Conclusion: The treatment of senile osteoporosis patients with salmon calcitonin combined with calcium carbonate can significantly improve patients with abnormal bone metabolism, promote the role of bone formation, worthy of clinical promotion.